A Prospective, Randomized, Open-label, Active-controlled, Multicenter Study to Evaluate the Efficacy and Safety of BAY 1192631 in Japanese Patients With MRSA Infections (Skin and Soft Tissue Infection [SSTI] and SSTI-related Bacteremia)

Trial Profile

A Prospective, Randomized, Open-label, Active-controlled, Multicenter Study to Evaluate the Efficacy and Safety of BAY 1192631 in Japanese Patients With MRSA Infections (Skin and Soft Tissue Infection [SSTI] and SSTI-related Bacteremia)

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Nov 2016

At a glance

  • Drugs Tedizolid (Primary) ; Tedizolid (Primary) ; Linezolid; Linezolid
  • Indications Bacteraemia; Methicillin-resistant Staphylococcus aureus infections; Skin and soft tissue infections
  • Focus Registrational; Therapeutic Use
  • Sponsors Bayer
  • Most Recent Events

    • 23 Nov 2016 Status changed from recruiting to completed.
    • 11 Jan 2016 Planned End Date changed from 1 Nov 2016 to 1 Jul 2017 as per ClinicalTrials.gov record.
    • 11 Jan 2016 Planned primary completion date changed from 1 Oct 2016 to 1 Jun 2017 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top